By Kate Snyder
A global biotech company based in Switzerland is in talks to lease space at the Atrium in Emeryville, according to a report from the San Francisco Business Times. Lonza Group AG is looking to lease approximately 150,000 square feet of the property located at 1650 65th St.
Located in the heart of Emeryville’s science hub, the Atrium has long been the subject of proposed development. PSAI Realty Partners and Griffin Capital Investors own the property, and last year, Longfellow Real Estate Partners planned to turn the site into a three-tower mixed-use development totaling 965,320 square feet, according to The Registry’s previous reporting. That plan included both residential and commercial office and lab space.
Since then, Longfellow has purchased the adjacent building at 6601 Shellmound St. and now plans to develop both properties into 190,000 square feet of lab space, according to the firm’s website. Representatives at Longfellow declined to comment about any lease negotiations with Lonza.
The location of the development is just off of Interstate 580 and extremely close to the San Francisco Bay. Major institutions such as the University of California Berkeley, Oakland Children’s Hospital and Pixar Animation Studios are nearby, according to Google Maps.
Founded in 1897 in the Swiss Alps, Lonza provides a wide range of services and products in the pharmaceutical, biotech and nutrition markets, according to the firm’s website. In 2020, the company supported more than 820 preclinical and clinical small and large molecules, more than 245 commercial small and large molecules and produced 230 billion capsules. Lonza operates across five continents and has more than 17,000 employees.
Longfellow partners with universities, institutions and companies for life sciences and technology projects, according to the firm’s website. The company is based in Boston and has targeted markets such as Boston, San Diego, North Carolina and San Francisco. Its clients have included Duke University, AstraZeneca, Illumina, Pfizer and others.